Nutex Health Inc. Delays 10-Q Filing

Clinigence Holdings ( (NUTX) ) has released a notification of late filing.

Nutex Health Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The company cites the need for additional time to analyze the classification of certain equity instruments and finalize its financial statements as the primary reasons for the delay. Despite these challenges, Nutex Health is working diligently to complete the review and expects to file the report within the five-calendar day extension period allowed by Rule 12b-25. The company anticipates significant changes in its financial results compared to the previous fiscal year, although specific details are not yet available. Nutex Health remains committed to compliance and transparency, as evidenced by the signature of Jon C. Bates, Chief Financial Officer, on the notification.

The most recent analyst rating on (NUTX) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Spark’s Take on NUTX Stock

According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.

Nutex Health’s overall stock score is driven by strong earnings call results and solid valuation metrics, indicating potential undervaluation. Financial performance is robust, though increased leverage poses a risk. Technical analysis shows mixed signals, with bearish momentum offset by neutral RSI and Stochastic indicators.

To see Spark’s full report on NUTX stock, click here.

More about Clinigence Holdings

Average Trading Volume: 233,833

Technical Sentiment Signal: Hold

Current Market Cap: $534M

Learn more about NUTX stock on TipRanks’ Stock Analysis page.